SG11201408232RA - 1,2,4-triazine-6-carboxamide kinase inhibitors - Google Patents
1,2,4-triazine-6-carboxamide kinase inhibitorsInfo
- Publication number
- SG11201408232RA SG11201408232RA SG11201408232RA SG11201408232RA SG11201408232RA SG 11201408232R A SG11201408232R A SG 11201408232RA SG 11201408232R A SG11201408232R A SG 11201408232RA SG 11201408232R A SG11201408232R A SG 11201408232RA SG 11201408232R A SG11201408232R A SG 11201408232RA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- avenue
- international
- triazine
- san
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261663499P | 2012-06-22 | 2012-06-22 | |
US13/841,472 US9040530B2 (en) | 2012-06-22 | 2013-03-15 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
PCT/US2013/046006 WO2013192049A2 (en) | 2012-06-22 | 2013-06-14 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408232RA true SG11201408232RA (en) | 2015-01-29 |
Family
ID=49769666
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408232RA SG11201408232RA (en) | 2012-06-22 | 2013-06-14 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
SG10201805392YA SG10201805392YA (en) | 2012-06-22 | 2013-06-14 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201805392YA SG10201805392YA (en) | 2012-06-22 | 2013-06-14 | 1,2,4-triazine-6-carboxamide kinase inhibitors |
Country Status (12)
Country | Link |
---|---|
US (1) | US9040530B2 (ru) |
EP (1) | EP2863748B1 (ru) |
JP (1) | JP6281984B2 (ru) |
CN (1) | CN104470363A (ru) |
AU (1) | AU2013277476B2 (ru) |
CA (1) | CA2876945C (ru) |
HK (1) | HK1209277A1 (ru) |
IL (1) | IL236057B (ru) |
IN (1) | IN2014KN02906A (ru) |
SG (2) | SG11201408232RA (ru) |
WO (1) | WO2013192049A2 (ru) |
ZA (1) | ZA201409256B (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | 1,2,4−トリアジン−6−カルボキサミド誘導体 |
EP2909174A1 (en) | 2012-10-19 | 2015-08-26 | F. Hoffmann-La Roche AG | Inhibitors of syk |
ES2914793T3 (es) * | 2012-11-08 | 2022-06-16 | Bristol Myers Squibb Co | Compuestos heterocíclicos sustituidos con amida, útiles como moduladores de la respuesta de IL-12, IL-23 y/o IFN-alfa |
WO2014109414A1 (ja) * | 2013-01-11 | 2014-07-17 | 富士フイルム株式会社 | 含窒素複素環化合物またはその塩 |
CN104870437A (zh) * | 2013-01-17 | 2015-08-26 | 四川恒康发展有限责任公司 | 三嗪化合物、其药用盐、异构体或水合物及其药物组合物 |
JP2016113366A (ja) * | 2013-03-29 | 2016-06-23 | 大鵬薬品工業株式会社 | アセトアミド基を有する1,2,4−トリアジン−6−カルボキサミド誘導体 |
EP3077388A1 (en) * | 2013-12-05 | 2016-10-12 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase |
SG10201911523YA (en) * | 2015-06-02 | 2020-02-27 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
CN109384774B (zh) * | 2017-08-11 | 2023-02-17 | 中国科学院上海药物研究所 | 一类多取代的吡嗪/三嗪酰胺类化合物及其制备方法和应用 |
EP4007757A4 (en) * | 2019-08-01 | 2023-07-19 | Integral Biosciences Pvt. Ltd. | HETEROCYCLIC COMPOUND AS KINASE INHIBITORS AND USES THEREOF |
US20230159520A1 (en) * | 2020-02-26 | 2023-05-25 | Beigene, Ltd. | Tyk-2 inhibitor |
WO2022032484A1 (zh) * | 2020-08-11 | 2022-02-17 | 北京诺诚健华医药科技有限公司 | 哒嗪-3-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
WO2023108536A1 (en) * | 2021-12-16 | 2023-06-22 | Lynk Pharmaceuticals Co. Ltd. | Tyk2 inhibitors and compositions and methods thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797706B1 (en) * | 1999-06-09 | 2004-09-28 | Yamanouchi Pharmaceutical Co., Ltd. | Heterocyclecarboxamide derivative |
JP4622047B2 (ja) * | 1999-06-09 | 2011-02-02 | アステラス製薬株式会社 | 新規なヘテロ環カルボキサミド誘導体 |
AU5108000A (en) * | 1999-06-10 | 2001-01-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel nitrogen-contaiing heterocyclic derivatives or salts thereof |
US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
KR101773313B1 (ko) * | 2008-04-16 | 2017-08-31 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
JP5878178B2 (ja) * | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | 1,2,4−トリアジン−6−カルボキサミド誘導体 |
US20130310387A1 (en) * | 2012-05-16 | 2013-11-21 | Novartis Ag | Monocyclic Heteroaryl Cycloalkyldiamine Derivatives |
-
2013
- 2013-03-15 US US13/841,472 patent/US9040530B2/en active Active
- 2013-06-14 SG SG11201408232RA patent/SG11201408232RA/en unknown
- 2013-06-14 WO PCT/US2013/046006 patent/WO2013192049A2/en unknown
- 2013-06-14 EP EP13807456.2A patent/EP2863748B1/en active Active
- 2013-06-14 IN IN2906KON2014 patent/IN2014KN02906A/en unknown
- 2013-06-14 CA CA2876945A patent/CA2876945C/en active Active
- 2013-06-14 JP JP2015518471A patent/JP6281984B2/ja active Active
- 2013-06-14 SG SG10201805392YA patent/SG10201805392YA/en unknown
- 2013-06-14 AU AU2013277476A patent/AU2013277476B2/en not_active Ceased
- 2013-06-14 CN CN201380037312.3A patent/CN104470363A/zh active Pending
-
2014
- 2014-12-04 IL IL236057A patent/IL236057B/en active IP Right Grant
- 2014-12-15 ZA ZA2014/09256A patent/ZA201409256B/en unknown
-
2015
- 2015-10-12 HK HK15109945.0A patent/HK1209277A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2013277476B2 (en) | 2016-12-15 |
HK1209277A1 (en) | 2016-04-01 |
CN104470363A (zh) | 2015-03-25 |
IL236057B (en) | 2018-08-30 |
JP2015520232A (ja) | 2015-07-16 |
ZA201409256B (en) | 2019-09-25 |
CA2876945C (en) | 2021-07-27 |
EP2863748A2 (en) | 2015-04-29 |
US9040530B2 (en) | 2015-05-26 |
WO2013192049A2 (en) | 2013-12-27 |
SG10201805392YA (en) | 2018-08-30 |
US20130345191A1 (en) | 2013-12-26 |
AU2013277476A1 (en) | 2015-01-22 |
WO2013192049A3 (en) | 2014-02-13 |
EP2863748A4 (en) | 2015-12-09 |
EP2863748B1 (en) | 2018-11-07 |
IN2014KN02906A (ru) | 2015-05-08 |
IL236057A0 (en) | 2015-02-01 |
CA2876945A1 (en) | 2013-12-27 |
JP6281984B2 (ja) | 2018-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408232RA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201407682TA (en) | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201804309PA (en) | Antibody molecules to april and uses thereof | |
SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
SG11201407533SA (en) | Antiviral compounds | |
SG11201407793TA (en) | Compounds and compositions for modulating egfr activity | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport |